Ken Griffin's position in Dianthus Therapeutics is currently worth $133M. That's 0.09% of their equity portfolio (275th largest holding). The investor owns 3.86% of the outstanding Dianthus Therapeutics stock. The first Dianthus Therapeutics trade was made in Q3 2023. Since then Ken Griffin bought shares eight more times and sold shares on two occasions. The stake costed the investor $56.9M, netting the investor a gain of 133% so far.